Sonoma Pharmaceuticals and Dyamed Biotech Announce Expanded Long-Term Partnership for New Territories and Products in Southeast Asia

WOODSTOCK, Ga.–(BUSINESS WIRE)–Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions and disinfectant use, and its long-time partner, Dyamed Biotech Pte Ltd., announce a renewed and expanded long-term partnership for Singapore, Malaysia, Indonesia and Thailand for multiple indications using Sonoma�s patented Microcyn® Technology.

Dyamed Biotech Pte Ltd., one of Sonoma’s first international partners, successfully commercializes Dermacyn® Wound Care, Dermacyn® Scarless for Scar Reduction, and Dermacyn® Ezyma Spray for itch relief associated with atopic dermatitis. Dyamed expects to launch Ocucyn® Eye Care and Oracyn® Oral Care in 2022. The Dermacyn® line of products are widely used at many hospitals throughout Singapore and Malaysia.

“We are so pleased with the performance of the Dermacyn® line of products which have helped provide modern wound care for both acute and chronic wounds in our hospitals and health care facilities for many years. With the additional indications using the patented Microcyn® Technology for scar reduction and atopic dermatitis treatment, we have had many patients see positive results,” said Dyamed Biotech Pte Ltd., CEO Theodore Tan.

“In addition, we look forward to the next year as we expand the Dermacyn® line of products for both eye and oral care in pharmacies and hospitals throughout Southeast Asia,” Mr. Tan added.

Bruce Thornton, Chief Operating Officer of Sonoma Pharmaceuticals said, “Dyamed has been a valued partner since 2004 and we are excited to support the next chapter of this special partnership. With the addition of the new territories of Indonesia and Thailand and new oral and eye care products, we expect Dyamed to expand its reach into both hospitals and pharmacy care. We are continuously seeking to expand our network of international distributors with quality partners like Dyamed to increase the reach of Sonoma products worldwide.”

About Dyamed Biotech Pte Ltd.,

Dyamed Biotech was established in 1998 to distribute quality medical diagnostic devices in Southeast Asia. The company is headquartered in Singapore and has a branch office in Malaysia. Dyamed Biotech distributes to public and private hospitals, clinics and pharmacies in Southeast Asia. Please contact us at +65 6848 1028 or visit our website at www.dyamed.com.

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care, disinfectant use and dermatological conditions. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 54 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Woodstock, Georgia, with manufacturing operations in Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “company”). These forward-looking statements are identified by the use of words such as “continue,” “develop” and “expand,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company’s products will not be as large as expected, the company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company’s cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Contacts

Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com